Scientific Advisory Board
Dr. Mark Bradley
Mark received his doctorate from the University of Oxford in 1989 under the supervision of Professor Sir Jack Baldwin, followed by post-doctoral studies at Harvard Medical School and returned to the UK as a Royal Society Fellow at Southampton University in the early 90’s. In 1996 at the age of 34 he was made a Professor of Combinatorial Chemistry. He has been elected to fellowships of both the Royal Society of Chemistry and Edinburgh, and has held the Novartis Young Investigator Award, the Zeneca Research Award for Organic Chemistry, the GlaxoWellcome Award for Innovative Chemistry, the Pfizer Award in Organic chemistry and more recently, the Novartis Chemistry Lectureship and the Award from the Society of Combinatorial Sciences. His group has published over 240 peer reviewed papers and more than 50 PhD students have graduated from his group.
Dr. Johan den Dunnen
Johan den Dunnen studied biology at the Catholic University Nijmegen (Nederland). In the same university he received his PhD in Molecular Biology for his work on the "Evolution of eye-lens crystallin genes" (promoter Prof.dr. JGG Schoenmakers). After his PhD he changed to the department of Human Genetics, Leiden University, and became involved in the search for the gene causing Duchenne and Becker muscular dystrophy. He is currently employed at the Center for Human and Clinical Genetics (LUMC, Leiden, Nederland), studying genetic disease in general and neuromuscular disorders (DMD/BMD, LGMD) in particular. As professor in "Medical Genome Technology" he focuses on the use of new high-throughput genome technology in research and diagnosis of genetic disease, in particular the development and innovation of mutation detection technologies and the application of next generation sequencing. His work resulted in several patents, amongst which for Array-on-Demand technology (licensed by FlexGen) and exon skipping as a potential treatment for Duchenne Muscular Dystrophy (licensed by Prosensa).
Dr. Michael S. Phillips
Dr. Michael S. Phillips, Ph.D. is the Director of Beaulieu-Saucier Université de Montréal Pharmacogenomics Centre located at the Montreal Heart Inistitute. He is also an Associate Professor in the faculty of Medicine at the University of Montreal and holds the Canada Research Chair in Translational Pharmacogenomics. The Pharmacogenomics Centre is a cutting-edge GLP clinical genotyping laboratory that supports clinical trial work and consists of two parallel components: a technology development platform and a clinical operations platform. His studies concentrate on the development, implementation, and integration of genomic technologies into healthcare. His main focus is in the area of personalized medicine offering specialized pharmacogenomics services and technologically advanced tools to clinical, industrial and academic projects.
Previously, Dr. Phillips was an associate director in the department of Pharmacogenetics at Orchid BioSciences, Inc. in Princeton NJ, a biotechnology company providing products, services and technologies for SNP scoring and genetic diversity analyses. While at Orchid, Dr. Phillips worked on pharmacogenomic screens for personalized medicine, led Orchid’s contribution to The SNP Consortium (TSC) and produced the first detailed haplotype map of chromosome 19. Prior to joining Orchid BioSciences, Dr. Phillips worked at Merck Research Laboratories, West Point, PA, with Dr. C. Thomas Caskey in the Department of Human Genetics, where he worked on projects in Type 1 Diabetes and multiple drug programs supporting pharmacogenetic studies. He obtained his Ph.D. from the University of Toronto, concentrating on the understanding and analysis of the gene responsible for the anesthetic induced pharmacogenetic condition of malignant hyperthermia.